CD4 and neoplasm: The efficacy of GV1001 is likely due to its ability to induce CD4 + T cells and CD8 + T cells in the immune system to mount an appropriate immune response, leading to a strong inflammatory response against tumours or tumour-draining lymph nodes, thereby achieving the effect of inhibiting tumours and prolonging patient survival [100].